Table 3Inclusion and exclusion criteria

CategoryCriteria
Study populationPatients with primary CRC and unresectable liver metastases due to lesion characteristics or underlying comorbidity
  • For KQ1 and KQ2, patients refractory to systemic chemotherapy
  • For KQ3 and KQ4, patients receiving local hepatic therapy as an adjunct to systemic chemotherapy
Time periodStudies with treatment dates after 2000 to represent current interventional approaches to local hepatic therapies
Publication languagesEnglish only
Admissible evidenceStudy designs
  • All study designs
  • Case reports that report on a rare adverse event
Other criteria
  • Extrahepatic disease permitted only if it is liver dominant
  • Studies must involve one or more of the interventions listed in the PICOTS
  • Studies must include at least one outcome measure listed in the PICOTS and the outcome must be extractable from data presented in the articles
  • To allow for the inclusion of all potentially relevant evidence, studies that deviated from our inclusion criteria by less than 10% were included (e.g., 5% of patients were HCC, or 9% of patients had documented extrahepatic disease)

CRC = colorectal cancer; KQ = Key Question; PICOTS = population, intervention, comparator, outcome, timing, setting

From: Methods

Cover of Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer
Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer [Internet].
Comparative Effectiveness Reviews, No. 93.
Belinson S, Chopra R, Yang Y, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.